U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C6H7N3O
Molecular Weight 137.1395
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ISONIAZID

SMILES

c1cnccc1C(=O)NN

InChI

InChIKey=QRXWMOHMRWLFEY-UHFFFAOYSA-N
InChI=1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10)

HIDE SMILES / InChI

Description
Curator's Comment:: Description was created based on several sources, including: http://www.drugbank.ca/drugs/DB00951 http://www.rxlist.com/isoniazid-drug.htm

Isoniazid is a bactericidal agent active against organisms of the genus Mycobacterium, specifically M. tuberculosis, M. bovis and M. kansasii. Isoniazid is recommended for all forms of tuberculosis in which organisms are susceptible. Isoniazid is a prodrug and must be activated by bacterial catalase. Isoniazid inhibits InhA, the enoyl reductase from Mycobacterium tuberculosis, by forming a covalent adduct with the NAD cofactor. The most frequent adverse reactions to isoniazid are those affecting the nervous system and the liver.

CNS Activity

Curator's Comment:: Isoniazid easily crosses the blood-brain barrier.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.75 nM [Ki]
Target ID: P9WIE4|||Q50553
Gene ID: NA
Gene Symbol: katG
Target Organism: Mycobacterium tuberculosis (strain CDC 1551 / Oshkosh)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Isoniazid

Approved Use

all forms of tuberculos in which organisms are susceptible. However, active tuberculosis must be treated with multiple concomitant antituberculosis medications to prevent the emergence of drug resistance. Also is recommended as preventive therapy

Launch Date

2.73024E10
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
8.7 mg/L
15 mg/kg bw 2 times / week multiple, oral
dose: 15 mg/kg bw
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ISONIAZID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
7.7 mg/L
15 mg/kg 2 times / week multiple, oral
dose: 15 mg/kg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ISONIAZID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
2.1 mg/L
5 mg/kg bw 1 times / day multiple, oral
dose: 5 mg/kg bw
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ISONIAZID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
2.8 mg/L
5 μg/kg bw 1 times / day multiple, oral
dose: 5 μg/kg bw
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ISONIAZID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
16.6 mg/L
15 mg/kg bw 2 times / week multiple, oral
dose: 15 mg/kg bw
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ISONIAZID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
3.1 mg/L
5 mg/kg bw 1 times / day multiple, oral
dose: 5 mg/kg bw
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ISONIAZID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
37.81 mg × h/L
15 mg/kg bw 2 times / week multiple, oral
dose: 15 mg/kg bw
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ISONIAZID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
53.17 mg × h/L
15 mg/kg 2 times / week multiple, oral
dose: 15 mg/kg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ISONIAZID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
6.96 mg × h/L
5 mg/kg bw 1 times / day multiple, oral
dose: 5 mg/kg bw
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ISONIAZID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
9.71 mg × h/L
5 μg/kg bw 1 times / day multiple, oral
dose: 5 μg/kg bw
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ISONIAZID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
71.52 mg × h/L
15 mg/kg bw 2 times / week multiple, oral
dose: 15 mg/kg bw
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ISONIAZID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
11.06 ng × h/L
5 mg/kg bw 1 times / day multiple, oral
dose: 5 mg/kg bw
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ISONIAZID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
86%
unknown, unknown
ISONIAZID plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
20 g single, oral
Overdose
Dose: 20 g
Route: oral
Route: single
Dose: 20 g
Sources: Page: p.294
healthy, 16
n = 1
Health Status: healthy
Age Group: 16
Sex: F
Population Size: 1
Sources: Page: p.294
Disc. AE: Nausea, Vomiting...
AEs leading to
discontinuation/dose reduction:
Nausea
Vomiting
Grand mal seizure
Lethargy
Coma
Sources: Page: p.294
20 g single, oral
Overdose
Dose: 20 g
Route: oral
Route: single
Dose: 20 g
Sources: Page: p.295
healthy, 16
n = 1
Health Status: healthy
Age Group: 16
Sex: F
Population Size: 1
Sources: Page: p.295
Disc. AE: Nystagmus, Hyperreflexia...
AEs leading to
discontinuation/dose reduction:
Nystagmus
Hyperreflexia
Sources: Page: p.295
112 mg/kg single, oral (max)
Overdose
Dose: 112 mg/kg
Route: oral
Route: single
Dose: 112 mg/kg
Sources:
unhealthy, 17
n = 1
Health Status: unhealthy
Condition: Tuberculosis
Age Group: 17
Sex: M
Population Size: 1
Sources:
Disc. AE: Lethargy, Seizures...
AEs leading to
discontinuation/dose reduction:
Lethargy
Seizures
Coma
Tachycardia
Sources:
25 g single, oral
Overdose
Dose: 25 g
Route: oral
Route: single
Dose: 25 g
Co-administed with::
pyridoxine, p.o(2.5 mg, single)
Sources: Page: p.2
healthy, 20
n = 1
Health Status: healthy
Age Group: 20
Sex: F
Population Size: 1
Sources: Page: p.2
Disc. AE: Generalized tonic-clonic seizure...
AEs leading to
discontinuation/dose reduction:
Generalized tonic-clonic seizure
Sources: Page: p.2
900 mg 1 times / week multiple, oral
Recommended
Dose: 900 mg, 1 times / week
Route: oral
Route: multiple
Dose: 900 mg, 1 times / week
Co-administed with::
rifapentine, p.o(900 mg; 1/week)
Sources: Page: p.2160
unhealthy, 25–47
n = 3986
Health Status: unhealthy
Condition: Tuberculosis
Age Group: 25–47
Sex: M+F
Population Size: 3986
Sources: Page: p.2160
Disc. AE: Hepatotoxicity, Hypersensitivity...
AEs leading to
discontinuation/dose reduction:
Hepatotoxicity (0.3%)
Hypersensitivity (2.9%)
Sources: Page: p.2160
3000 mg single, oral
Overdose
Dose: 3000 mg
Route: oral
Route: single
Dose: 3000 mg
Sources: Page: 73/127
healthy, 7
n = 1
Health Status: healthy
Age Group: 7
Sex: M
Population Size: 1
Sources: Page: 73/127
Disc. AE: Seizures, Metabolic acidosis...
AEs leading to
discontinuation/dose reduction:
Seizures (severe)
Metabolic acidosis
Coma
Oliguria
Sources: Page: 73/127
900 mg 3 times / week multiple, oral
Recommended
Dose: 900 mg, 3 times / week
Route: oral
Route: multiple
Dose: 900 mg, 3 times / week
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Tuberculosis
Sources: Page: p.1
Disc. AE: Hepatitis...
AEs leading to
discontinuation/dose reduction:
Hepatitis (grade 5)
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Coma Disc. AE
20 g single, oral
Overdose
Dose: 20 g
Route: oral
Route: single
Dose: 20 g
Sources: Page: p.294
healthy, 16
n = 1
Health Status: healthy
Age Group: 16
Sex: F
Population Size: 1
Sources: Page: p.294
Grand mal seizure Disc. AE
20 g single, oral
Overdose
Dose: 20 g
Route: oral
Route: single
Dose: 20 g
Sources: Page: p.294
healthy, 16
n = 1
Health Status: healthy
Age Group: 16
Sex: F
Population Size: 1
Sources: Page: p.294
Lethargy Disc. AE
20 g single, oral
Overdose
Dose: 20 g
Route: oral
Route: single
Dose: 20 g
Sources: Page: p.294
healthy, 16
n = 1
Health Status: healthy
Age Group: 16
Sex: F
Population Size: 1
Sources: Page: p.294
Nausea Disc. AE
20 g single, oral
Overdose
Dose: 20 g
Route: oral
Route: single
Dose: 20 g
Sources: Page: p.294
healthy, 16
n = 1
Health Status: healthy
Age Group: 16
Sex: F
Population Size: 1
Sources: Page: p.294
Vomiting Disc. AE
20 g single, oral
Overdose
Dose: 20 g
Route: oral
Route: single
Dose: 20 g
Sources: Page: p.294
healthy, 16
n = 1
Health Status: healthy
Age Group: 16
Sex: F
Population Size: 1
Sources: Page: p.294
Hyperreflexia Disc. AE
20 g single, oral
Overdose
Dose: 20 g
Route: oral
Route: single
Dose: 20 g
Sources: Page: p.295
healthy, 16
n = 1
Health Status: healthy
Age Group: 16
Sex: F
Population Size: 1
Sources: Page: p.295
Nystagmus Disc. AE
20 g single, oral
Overdose
Dose: 20 g
Route: oral
Route: single
Dose: 20 g
Sources: Page: p.295
healthy, 16
n = 1
Health Status: healthy
Age Group: 16
Sex: F
Population Size: 1
Sources: Page: p.295
Coma Disc. AE
112 mg/kg single, oral (max)
Overdose
Dose: 112 mg/kg
Route: oral
Route: single
Dose: 112 mg/kg
Sources:
unhealthy, 17
n = 1
Health Status: unhealthy
Condition: Tuberculosis
Age Group: 17
Sex: M
Population Size: 1
Sources:
Lethargy Disc. AE
112 mg/kg single, oral (max)
Overdose
Dose: 112 mg/kg
Route: oral
Route: single
Dose: 112 mg/kg
Sources:
unhealthy, 17
n = 1
Health Status: unhealthy
Condition: Tuberculosis
Age Group: 17
Sex: M
Population Size: 1
Sources:
Seizures Disc. AE
112 mg/kg single, oral (max)
Overdose
Dose: 112 mg/kg
Route: oral
Route: single
Dose: 112 mg/kg
Sources:
unhealthy, 17
n = 1
Health Status: unhealthy
Condition: Tuberculosis
Age Group: 17
Sex: M
Population Size: 1
Sources:
Tachycardia Disc. AE
112 mg/kg single, oral (max)
Overdose
Dose: 112 mg/kg
Route: oral
Route: single
Dose: 112 mg/kg
Sources:
unhealthy, 17
n = 1
Health Status: unhealthy
Condition: Tuberculosis
Age Group: 17
Sex: M
Population Size: 1
Sources:
Generalized tonic-clonic seizure Disc. AE
25 g single, oral
Overdose
Dose: 25 g
Route: oral
Route: single
Dose: 25 g
Co-administed with::
pyridoxine, p.o(2.5 mg, single)
Sources: Page: p.2
healthy, 20
n = 1
Health Status: healthy
Age Group: 20
Sex: F
Population Size: 1
Sources: Page: p.2
Hepatotoxicity 0.3%
Disc. AE
900 mg 1 times / week multiple, oral
Recommended
Dose: 900 mg, 1 times / week
Route: oral
Route: multiple
Dose: 900 mg, 1 times / week
Co-administed with::
rifapentine, p.o(900 mg; 1/week)
Sources: Page: p.2160
unhealthy, 25–47
n = 3986
Health Status: unhealthy
Condition: Tuberculosis
Age Group: 25–47
Sex: M+F
Population Size: 3986
Sources: Page: p.2160
Hypersensitivity 2.9%
Disc. AE
900 mg 1 times / week multiple, oral
Recommended
Dose: 900 mg, 1 times / week
Route: oral
Route: multiple
Dose: 900 mg, 1 times / week
Co-administed with::
rifapentine, p.o(900 mg; 1/week)
Sources: Page: p.2160
unhealthy, 25–47
n = 3986
Health Status: unhealthy
Condition: Tuberculosis
Age Group: 25–47
Sex: M+F
Population Size: 3986
Sources: Page: p.2160
Coma Disc. AE
3000 mg single, oral
Overdose
Dose: 3000 mg
Route: oral
Route: single
Dose: 3000 mg
Sources: Page: 73/127
healthy, 7
n = 1
Health Status: healthy
Age Group: 7
Sex: M
Population Size: 1
Sources: Page: 73/127
Metabolic acidosis Disc. AE
3000 mg single, oral
Overdose
Dose: 3000 mg
Route: oral
Route: single
Dose: 3000 mg
Sources: Page: 73/127
healthy, 7
n = 1
Health Status: healthy
Age Group: 7
Sex: M
Population Size: 1
Sources: Page: 73/127
Oliguria Disc. AE
3000 mg single, oral
Overdose
Dose: 3000 mg
Route: oral
Route: single
Dose: 3000 mg
Sources: Page: 73/127
healthy, 7
n = 1
Health Status: healthy
Age Group: 7
Sex: M
Population Size: 1
Sources: Page: 73/127
Seizures severe
Disc. AE
3000 mg single, oral
Overdose
Dose: 3000 mg
Route: oral
Route: single
Dose: 3000 mg
Sources: Page: 73/127
healthy, 7
n = 1
Health Status: healthy
Age Group: 7
Sex: M
Population Size: 1
Sources: Page: 73/127
Hepatitis grade 5
Disc. AE
900 mg 3 times / week multiple, oral
Recommended
Dose: 900 mg, 3 times / week
Route: oral
Route: multiple
Dose: 900 mg, 3 times / week
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Tuberculosis
Sources: Page: p.1
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Hepatotoxicity of rifampicin and isoniazid in children.
1975 May
Antituberculosis activity of certain antifungal and antihelmintic drugs.
1999
Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
1999 Dec
High-dose isoniazid therapy for isoniazid-resistant murine Mycobacterium tuberculosis infection.
1999 Dec
Lymphocyte transformation test for the evaluation of adverse effects of antituberculous drugs.
1999 Feb 25
[A case of pulmonary tuberculosis with acute renal failure caused by readministration of rifampicin].
1999 Nov
Antimycobacterial activity of new ortho-, meta- and para-toluidine derivatives.
1999 Nov-Dec
Drug-induced lupus nephritis in HIV infection.
1999 Oct
Outcome of multidrug-resistant tuberculosis in human immunodeficiency virus-infected patients.
1999 Sep
Activity of moxifloxacin against mycobacteria.
1999 Sep
Genomic mutations in the katG, inhA and aphC genes are useful for the prediction of isoniazid resistance in Mycobacterium tuberculosis isolates from Kwazulu Natal, South Africa.
2000
Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999.
2000 Apr
Antimycobacterial activities of novel levofloxacin analogues.
2000 Aug
Acute isoniazid neurotoxicity during preventive therapy.
2000 Feb
Use of genomics and combinatorial chemistry in the development of new antimycobacterial drugs.
2000 Feb 1
[Isoniazid-induced hepatic failure. Report of a case].
2000 Jan-Mar
Inactivation of the inhA-encoded fatty acid synthase II (FASII) enoyl-acyl carrier protein reductase induces accumulation of the FASI end products and cell lysis of Mycobacterium smegmatis.
2000 Jul
Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid.
2000 Jul 4
A multicentre study of the early bactericidal activity of anti-tuberculosis drugs.
2000 Jun
Increased incidence of peripheral neuropathy with co-administration of stavudine and isoniazid in HIV-infected individuals.
2000 Mar 31
Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis.
2000 Nov
Antepartum or postpartum isoniazid treatment of latent tuberculosis infection.
2000 Nov
Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis.
2000 Sep
On-column amperometric detection of ofloxacin and pasiniazid in urine by capillary electrophoresis with an improved fractured joint and small detection cell.
2001 Apr
Evaluation of tuberculosis control by periodic or routine susceptibility testing in previously treated cases.
2001 Apr
Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.
2001 Apr 20
Ion interaction reagent reversed-phase high-performance liquid chromatography determination of anti-tuberculosis drugs and metabolites in biological fluids.
2001 Apr 25
[Disseminated disease by Mycobacterium kansasii resistant to isoniazid and rifampin in patients] with AIDS].
2001 Feb
Connatal tuberculosis in an extremely low birth weight infant: case report and management of exposure to tuberculosis in a neonatal intensive care unit.
2001 Feb
TB prevention in HIV clinics in New York City.
2001 Feb
Drug-resistant tuberculosis in Taipei, 1996-1999.
2001 Feb
Incentives vs outreach workers for latent tuberculosis treatment in drug users.
2001 Feb
Outbreak of multidrug-resistant tuberculosis at a methadone treatment program.
2001 Jan
Low rate of emergence of drug resistance in sputum positive patients treated with short course chemotherapy.
2001 Jan
Prevalence of drug-resistant tuberculosis in an HIV endemic area in northern Thailand.
2001 Jan
Does tuberculosis after kidney transplantation follow the trend of tuberculosis in general population?
2001 Jan
Can a nine-month regimen be used to treat isoniazid resistant tuberculosis diagnosed after standard treatment is started?
2001 Jan
Survey for tuberculosis in a tribal population in North Arcot District.
2001 Mar
Enhancement of antibiotic activity against poly-drug resistant Mycobacterium tuberculosis by phenothiazines.
2001 Mar
Mycobacterial FurA is a negative regulator of catalase-peroxidase gene katG.
2001 Mar
First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol.
2001 Mar
Active site structure of the catalase-peroxidases from Mycobacterium tuberculosis and Escherichia coli by extended X-ray absorption fine structure analysis.
2001 Mar 9
Experimental in vitro efficacy study on the interaction of epiroprim plus isoniazid against Mycobacterium tuberculosis.
2001 Mar-Apr
Efficacy of chemotherapy for prostatic tuberculosis-a clinical and histologic follow-up study.
2001 May
Patents

Sample Use Guides

Adults: 5 mg/kg up to 300 mg daily in a single dose; or 15 mg/kg up to 900 mg/day, two or three times/week Children: 10 mg/kg to15 mg/kg up to 300 mg daily in a single dose; or 20 mg/kg to 40 mg/kg up to 900 mg/day, two or three times/week
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment:: MIC90 (minimum inhibitory concentration at which 90% of the test strains were inhibited) of isoniazid for Mycobacterium tuberculosis is 1.56 μg/ml.
1.56 μg/ml
Name Type Language
ISONIAZID
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN  
Official Name English
HYDRAZID
Common Name English
ISONIAZID COMPONENT OF RIFATER
Common Name English
ISOBICINA
Common Name English
ERALON
Common Name English
4-PYRIDINECARBOXYLIC ACID, HYDRAZIDE
Common Name English
INH
Brand Name English
STANOZIDE
Brand Name English
ISONIAZID [USP MONOGRAPH]
Common Name English
HYZYD
Brand Name English
ISONICOTINIC ACID HYDRAZIDE
WHO-IP  
Systematic Name English
MYBASAN
Common Name English
NYDRAZID
Brand Name English
4-PYRIDINECARBOXYLIC ACID HYDRAZIDE [WHO-IP]
Common Name English
CEDIN
Common Name English
ISONIAZID [ORANGE BOOK]
Common Name English
ATCOTIBINE
Common Name English
ISONIAZID [JAN]
Common Name English
ISONIAZID [WHO-DD]
Common Name English
COTINAZIN
Common Name English
RIMIFON
Brand Name English
DITUBIN
Common Name English
ARMAZID
Common Name English
NEUMANDIN
Common Name English
IPCAZIDE
Common Name English
TEEBACONIN
Common Name English
ISONIAZID [EP MONOGRAPH]
Common Name English
ISONICOTINIC ACID HYDRAZIDE [WHO-IP]
Common Name English
ISONIAZID [USP-RS]
Common Name English
ISONIAZID COMPONENT OF RIFAMATE
Common Name English
HIDRASONIL
Common Name English
ISONIAZID [WHO-IP]
Common Name English
DINACRIN
Common Name English
ISONIAZID [MI]
Common Name English
ISONIAZID [INN]
Common Name English
RIFAMATE COMPONENT ISONIAZID
Common Name English
ISONIAZID [MART.]
Common Name English
ARMAZIDE
Common Name English
NSC-9659
Code English
ERTUBAN
Common Name English
ISONIAZIDUM [WHO-IP LATIN]
Common Name English
RIFATER COMPONENT ISONIAZID
Common Name English
ISONICOTINYLHYDRAZINE
Systematic Name English
TISIODRAZIDA
Common Name English
DIANICOTYL
Common Name English
DOW-ISONIAZID
Brand Name English
ISONICOTINIC ACID HYDRAZIDE [IARC]
Common Name English
ISONIAZID [EP]
Common Name English
ISONIAZID [HSDB]
Common Name English
ISONICOTAN
Common Name English
ISCOTIN
Brand Name English
ISONIAZID [VANDF]
Common Name English
ISIDRINA
Common Name English
Classification Tree Code System Code
NDF-RT N0000175483
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.2.4 (ETH/ISO)
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
WHO-ATC J04AM01
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.2.4
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
WHO-ATC J04AC01
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
WHO-VATC QJ04AC51
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
WHO-ATC J04AM04
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
WHO-ATC J04AM06
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
WHO-VATC QJ04AM01
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
WHO-ATC J04AM05
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
NCI_THESAURUS C280
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
WHO-ATC J04AM03
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.2.4 (ETH/ISO/PYR/RIF)
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.2.4 (ETH/ISO/RIF)
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
WHO-VATC QJ04AM02
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
WHO-VATC QJ04AM04
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
LIVERTOX 521
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
WHO-VATC QJ04AM03
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
FDA ORPHAN DRUG 6585
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
WHO-ATC J04AM08
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
WHO-VATC QJ04AC01
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
WHO-VATC QJ04AM05
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
WHO-ATC J04AM02
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.2.4 (ISO/RIF)
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
WHO-VATC QJ04AM06
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.2.4 (ISO/PYR/RIF)
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
WHO-ATC J04AC51
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
WHO-ATC J04AM07
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
Code System Code Type Description
HSDB
1647
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
PRIMARY
FDA UNII
V83O1VOZ8L
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
PRIMARY
DRUG CENTRAL
1497
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
PRIMARY
RXCUI
6038
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
PRIMARY RxNorm
MERCK INDEX
M6502
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
PRIMARY Merck Index
EVMPD
SUB08326MIG
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
PRIMARY
LACTMED
Isoniazid
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
PRIMARY
ChEMBL
CHEMBL64
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
PRIMARY
INN
4188
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
PRIMARY
CAS
54-85-3
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
PRIMARY
ECHA (EC/EINECS)
200-214-6
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
PRIMARY
USP_CATALOG
1349706
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
PRIMARY USP-RS
MESH
D007538
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
PRIMARY
PUBCHEM
3767
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
PRIMARY
DRUG BANK
DB00951
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
PRIMARY
EPA CompTox
54-85-3
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
ISONIAZID
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
PRIMARY Description: Colourless crystals or a white, crystalline powder; odourless. Solubility: Soluble in 8 parts of water and in 40 parts of ethanol (~750 g/l) TS; very slightly soluble in ether R. Category: Tuberculostatic. Storage: Isoniazid should be kept in a well-closed container, protected from light. Definition: Isoniazid contains not less than 98.0% and not more than 101.0% of C6H7N3O, calculated with reference to the dried substance.
NCI_THESAURUS
C600
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
PRIMARY
WIKIPEDIA
ISONIAZID
Created by admin on Fri Jun 25 20:57:22 UTC 2021 , Edited by admin on Fri Jun 25 20:57:22 UTC 2021
PRIMARY